ArticleJournal of managed care & specialty pharmacy2025
AMCP Market Insights: Payer best practices in food allergy management.
Article in Journal of managed care & specialty pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of biologics in food allergy management is an emerging area; therefore, guidance is required for payers to ensure appropriate access. AMCP Market Insights undertook a multiphase program to refine proposed actions from a previous program into a set of payer best practices in food allergy management and to gain insights on gaps in knowledge regarding food allergy mechanisms and management. The program included a national survey of managed care professionals, individual expert interviews, and a moderated expert roundtable. Best practices identified were to increase awareness of food allergy mechanisms, mitigate accidental exposure impact, support behavioral health needs, ensure access to emergency medications, consider social determinants of health and equity, and assess cost-effectiveness. Best practices specific to omalizumab, which is currently the only biologic approved by the US Food and Drug Administration, were to establish appropriate initial coverage criteria and develop appropriate ongoing coverage criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.